IgG:FcγRIIb Signaling on Mast Cells Blocks Allergic Airway Inflammation
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146779 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Cynthia Kanagaratham und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Receptors, IgG, Inflammation, Mast Cells. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health, Food Allergy Science Initiative.
Abstract (Originalsprache)
IgG antibodies, signaling via the inhibitory receptor, FcγRIIb, are potent inhibitors of IgE-mediated mast cell activation. We have previously reported that in addition to blocking mast cell degranulation, inhibitory IgG signals shut down a proinflammatory transcriptional program in which mast cells produce cytokines and chemokines known to drive type 2 tissue inflammation. To determine whether such effects of allergen-specific IgG can modulate allergic inflammation in vivo, we examined the airways of mice sensitized to ovalbumin (OVA) by intraperitoneal injection and then challenged with intranasal OVA. Pretreatment with allergen-specific IgG significantly reduced the recruitment of inflammatory cells, including macrophages and eosinophils, into the lungs of OVA-sensitized mice. The bronchoalveolar lavage fluid of OVA-challenged mice contained elevated levels of chemokine ligands (CCL2 and CCL24) and interleukin-5, a response that was markedly blunted in animals receiving allergen-specific IgG. IgG-treated animals exhibited attenuated allergen-induced production of IgE, IL-4, and IL-13, along with impaired OVA-induced goblet cell hyperplasia and Muc5ac expression and suppressed airway hyperresponsiveness, consistent with a shift away from a Th2 response. Using mice with a lineage-specific deletion of FcγRIIb, we demonstrated that each of these protective effects of IgG was dependent upon the expression of this receptor on mast cells. Overall, our findings establish that allergen-specific IgG can reduce allergen-driven airway inflammation and airway hyperresponsiveness and point to a mechanistic basis for the therapeutic benefit of aeroallergen-specific IgG therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Boston Children's Hospital, Boston, MA 02115, USA.
- Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
ORCID-Profile: Cynthia Kanagaratham, Kameryn N Furiness
Förderung
- NIH HHS
- National Institutes of Health
- Food Allergy Science Initiative
- Fonds de recherche Québec—Santé
- American Lung Association
Zitieren
APA
Kanagaratham, C., El Ansari, Y. S., Furiness, K. N., & Oettgen, H. C. (2025). IgG:FcγRIIb Signaling on Mast Cells Blocks Allergic Airway Inflammation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146779
Vancouver
Kanagaratham C, El Ansari YS, Furiness KN, Oettgen HC. IgG:FcγRIIb Signaling on Mast Cells Blocks Allergic Airway Inflammation. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146779
BibTeX
@article{Kanagaratham2025,
author = {Kanagaratham, Cynthia and El Ansari, Yasmeen S and Furiness, Kameryn N and Oettgen, Hans C},
title = {IgG:FcγRIIb Signaling on Mast Cells Blocks Allergic Airway Inflammation},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146779}
}
EUVIMED